Last reviewed · How we verify

NCT02041221

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SPARC1316

Completed Phase 1/Phase 2 Results posted Last updated 21 April 2016
What this trial tests

Phase 1/Phase 2 trial testing SPARC1316 Dose 1 in Asthma in 64 participants. Completed in 1 November 2014.

Timeline
1 January 2014
Primary endpoint
1 November 2014
1 November 2014

Quick facts

Lead sponsorSun Pharma Advanced Research Company Limited
PhasePhase 1/Phase 2
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposetreatment
Enrollment64
Start date1 January 2014
Primary completion1 November 2014
Estimated completion1 November 2014
Sites1 location across United Kingdom

Drugs / interventions tested

Conditions studied

Sponsor

Sun Pharma Advanced Research Company Limited — full company profile →

Who can join

Adults 18 to 65, any sex, with Asthma. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Sponsor's own description

Sun Pharma Advanced Research company Limited has developed a dry powder inhaler of compound SPARC1316 for oral inhalation. This clinical study is a Phase I/IIa study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple ascending doses of S0597 administered by oral inhalation to healthy volunteers and asthma patients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Asthma

Currently open trials in the same condition.

Other Sun Pharma Advanced Research Company Limited trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02041221.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing